A BIOEQUIVALENCE STUDY OF 2 BRANDS OF DOXYCYCLINE CAPSULES

Authors
SAKET M QAISI A ABDELRAZZAK M AMRO B TUTUNJI M GHARAIBEH M ZMEILI S MUTI H
Citation
M. Saket et al., A BIOEQUIVALENCE STUDY OF 2 BRANDS OF DOXYCYCLINE CAPSULES, Current therapeutic research, 54(1), 1993, pp. 15-22
Citations number
11
Categorie Soggetti
Pharmacology & Pharmacy","Medicine, Research & Experimental
Journal title
Current therapeutic research → ACNP
ISSN journal
0011393X
Volume
54
Issue
1
Year of publication
1993
Pages
15 - 22
Database
ISI
SICI code
0011-393X(1993)54:1<15:ABSO2B>2.0.ZU;2-C
Abstract
Bioequivalence of two preparations of doxycycline (Doxydar(TM) 100-mg capsules and Vibramycin(TM) 100-mg capsules) were compared in a two-wa y crossover study. Pharmacokinetic parameters were determined for both formulations, including area under the concentration-time curve, mean maximum plasma concentration, time to maximum concentration, half-lif e, and the terminal rate of elimination. Statistical analysis revealed that differences between the two formulations were not statistically significant. Quality control data, including assay and disintegration, indicated that both products met the in-house specifications. It is c oncluded that Doxydar 100 mg is bioequivalent to Vibramycin 100 mg.